In recent years, AI technology has revolutionized the medical field. From assisted diagnosis to medical imaging enablement to drug research and development, the power of AI is gradually penetrating and reshaping every corner of the medical industry.

In this context, how can investors seize definitive opportunities in AI healthcare? Which companies can stand out and become the mainstay of the industry?

According to industry observers, AI medical companies that are the first to explore commercial implementation paths and have self-hematopoietic capabilities are more valuable for investment. These companies generally have strong R&D strength and market insight, and can gain a foothold in fierce market competition and achieve continuous growth and development, such as Eagle Hitomi Technology (02251.HK).

Recently, Eagle Hitomi Technology announced its latest interim report. While revenue achieved double-digit year-on-year growth, profitability also increased dramatically, providing a strong guarantee for the company's steady operation and global strategic expansion.

Financial reports show that in the first half of the year, Eagle Hitomi Technology achieved revenue of 93.71 million yuan, an increase of 13.6% over the previous year. The gross profit reached 53.756 million yuan, and the gross margin was 57.4%. The revenue growth was mainly due to the rapid expansion of the two major sectors, Eagle Eye Healthcare and Eagle Eye Health, especially the active layout of domestic and foreign markets, which enabled the company to maintain its lead in fierce competition.

It can be said that Eagle Hitomi Technology achieved all-round, qualitative growth in the first half of the year. Next, we might as well discuss it further from an investor's perspective. How should we view this report card?

1. The three major sectors go hand in hand, and the global layout is progressing steadily

To understand why Eagle Eye is able to achieve such high-quality growth, we must first understand one thing: What exactly is Eagle Hitomi doing?

Looking at the business structure, the revenue sources of Eagle Hitomi Technology are mainly divided into three major sectors: Eagle Hitomi Healthcare, Eagle Hitomi Health, and Eagle Eye Health.

In the first half of this year, all three businesses achieved steady development. Among them, the Eagle Eye Health business achieved revenue of 36.45 million yuan, an increase of 22.1% over the previous year; the Eagle Eye Health business achieved revenue of 19.27 million yuan; and the Eagle Eye Health business achieved revenue of 37.99 million yuan, an increase of 22.7% over the previous year.

Among them, the significant increase in service outlets has led to the overall expansion of Eagle Hitomi Technology. In the first half of the year, the number of active service outlets of the company increased significantly from 3,331 in the same period last year to 78.6% to 5,950. It can be seen from this that major businesses have gone hand in hand, and the continuous expansion of service outlets has promoted the company's development. The commercialization of Eagle Hitomi Technology has continued to be realized, and the performance level is being released. In the future, as it strengthens overseas markets and continues to expand commercialization channels, it will also further optimize its financial level.

Although the layout of Eagle Eye Technology in overseas markets is in its infancy, it has successfully obtained admission to many countries, especially in Southeast Asia and the Middle East, demonstrating the company's strong international expansion capabilities.

According to information, at present, the company's products have successfully entered the 27 CE EU countries, Malaysia, Singapore, Thailand in Southeast Asia, and the United Arab Emirates, Saudi Arabia, and South Africa in the Middle East. As its products are gradually accepted by the local market, the increased sales and market share will directly increase the company's operating income and profit, thereby expanding the brand awareness and market influence of Eagle Eye Technology in the region and further consolidating the company's market competitiveness.

More importantly, successful regional expansion can bring good demonstration effects, thereby attracting more investment and partners, and laying a solid foundation for the company's continued growth and global layout.

2. AI “black technology” is constantly emerging, empowering primary care

Looking to the future, how much room does Eagle Hitomi Technology have?

From a macro perspective, top-level design continues to step up efforts to promote the deep integration of AI technology with the medical industry.

For example, the promulgation of a series of policies such as “Opinions on Further Improving the Medical and Health Service System”, “Report on the Work of the Government”, and “Notice on Issuing the 2.0 Group Payment Plan by Patient Group and Disease Type and Further Promoting Related Work” is rapidly driving the integration of AI and medical care, helping medical services develop in the direction of lower cost, higher efficiency, and higher quality “value medicine” in terms of medical image analysis, etc.

Furthermore, the primary care sector in China is facing challenges such as a shortage of medical personnel and insufficient service capacity. Coupled with the increasing burden of basic medical care and public health tasks carried out by primary health service institutions, it has become particularly urgent to improve primary service capacity.

Therefore, many industry insiders and brokerage institutions are optimistic about the growth potential of the AI medical market. The Global Market Insights report predicts that the “AI+ Healthcare” market will grow at a compound annual growth rate of more than 29%, and the market size is expected to reach 70 billion US dollars by 2032; some experts expect the compound annual growth rate of China's “AI+ Healthcare” market to exceed 30% in the next ten years; China Merchants Securities also pointed out that the global “AI+ Healthcare” market has exceeded 5 billion US dollars and is expected to continue to grow rapidly.

Needless to say, AI healthcare has shown huge market potential and development prospects, which indicates that it will be the next golden track.

Focusing on the company, Eagle Hitomi Technology's forward-looking strategic layout accurately fits the development trend of “AI+ healthcare”, and further empowers primary care and social responsibility beyond the field of eye health.

In the first half of the year, the company continued to promote innovative research and development of its products. Currently, the company's pipeline covers a wide range of artificial intelligence software (SaMD), health risk assessment systems, and corresponding intelligent hardware devices provided to medical institutions and the health sector, creating a solution integrating software and hardware.

Specifically, the company has formed a medical AI product matrix for retinal AI, myopia prevention and control AI, and visual training AI.

Among them, retinal AI products solve the huge medical demand gap for early detection and diagnosis of chronic diseases and fundus complications. The developed early detection, diagnosis and health risk assessment solutions for artificial intelligent retinal image recognition are expected to cover a wide range of diseases and lesions.

Fundus retinal AI products cover software medical devices for testing and diagnosis, health risk assessment solutions, and proprietary artificial intelligence hardware devices, forming an integrated software and hardware solution based on artificial intelligence.

In addition, AI eye movement and AI training guidance modules have been added to visual training AI products, which are widely recognized by professional doctors and customers. In terms of AI for myopia prevention and control, the company uses more advanced R&D capabilities than its peers to develop non-invasive light management products.

Through the deep application of AI technology, Eagle Hitomi Technology has effectively mitigated the problem of the imbalance in doctor-patient ratio in primary medical institutions. For example, the AirDoc-aifundus (1.0) system, which covers 1,533 primary medical institutions across the country, not only greatly improved screening efficiency, but also significantly improved the uneven distribution of medical resources. Furthermore, the system has successfully helped doctors detect thousands of cases of severe retinal disease in the early stages, greatly improving the cure rate and quality of life of patients.

At the same time, relying on the successful experience of pioneers in the AI medical field, Eagle Hitomi Technology continued to deepen the integration of AI and healthcare in the first half of the year, further enriching the product ecosystem and consolidating its leading position in the industry.

For example, the AI eye movement technology successfully developed by the company, based on ordinary RGB cameras, has been integrated into visual training AI products to form a unique AI visual training digital therapy. At the same time, the upgraded version of the AI product for visual training has also added AI eye movement and AI training guidance functions, and an AI visual training box (VisionBox) for optometry channels has been launched.

In terms of hardware, the AIFUNDUS-M multi-modal fundus camera has been developed and registered to fully upgrade hardware, software, algorithms and solutions. At the same time, the company is also actively promoting the research and development of non-invasive phototherapy devices and continuing to expand the product line.

Furthermore, the Wanyu Big Model developed by the company has successfully passed the national in-depth synthesis service algorithm registration. This will greatly support the decision-making process of medical professionals, improve the quality of patient care, promote the popularization and application of medical knowledge, and inject new impetus into the development of the AI medical industry.

III. Future prospects under steady growth

Overall, Eagle Hitomi Technology is gradually unlocking its huge commercial value through steady revenue growth and continuous technological innovation. With the deepening of the global layout and the continuous enrichment of product lines, Eagle Hitomi Technology is undoubtedly becoming a benchmark enterprise in the AI medical field, and its intrinsic value will surely be fully recognized by the market in the future.